MedTrace Logo

Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer

NCT05700227 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2026-04-21

No results posted yet for this study

Summary

This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle-invasive bladder cancer will translate into a decreased rate of acute (assessed weekly during chemo-radiotherapy) grade 3 or greater gastrointestinal/genitourinary toxicity compared with the historically reported rate for non-adaptive radiation therapy. The Common Terminology Criteria for Adverse Events (CTCAE) version 5 assessment tool will be utilized.

Conditions

  • Muscle Invasive Bladder Urothelial Carcinoma

Interventions

RADIATION

Daily Adaptive External Beam Radiation Therapy

Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • Varian, a Siemens Healthineers Company

    lead INDUSTRY

Principal Investigators

  • Brian Baumann, MD · Springfield Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2024-05-09
Completion
2024-05-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05700227 on ClinicalTrials.gov